Form 4: Verona Pharma CFO Mark Hahn Reports Changes in Beneficial Ownership

Mark Hahn, CFO of Verona Pharma plc, reports changes in beneficial ownership due to tax withholding obligations related to vesting Restricted Share Units.

Summary

• On May 1, 2024, Mark Hahn, the Chief Financial Officer of Verona Pharma plc, reported changes in his beneficial ownership of the company's securities.
• The changes are due to the withholding of 88,544 Ordinary Shares to satisfy tax obligations related to the vesting of previously reported Restricted Share Units.
• The price per share for the transaction is $1.9313, calculated based on the closing price of Verona Pharma's American Depositary Shares (ADSs) on April 30, 2024, divided by eight.
• Following the transaction, Hahn beneficially owns 14,943,032 Ordinary Shares, including those underlying Restricted Share Units and ADSs.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding changes in beneficial ownership due to tax obligations. It doesn't convey any particularly positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and tax obligations, common among publicly traded companies. It doesn't necessarily indicate a strategic shift or major event for Verona Pharma.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, as mandated by the SEC.
• The transaction described is typical of tax withholding related to the vesting of equity compensation, a common practice across publicly traded companies.
• Similar filings can be observed for executives at comparable pharmaceutical companies like AstraZeneca, GlaxoSmithKline, and Novartis.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it relates to tax obligations of a company executive.
• The filing ensures transparency regarding executive ownership, which is important for investor confidence.

Key Dates